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Volume 58, Number 4 Abstracts 1147Conclusions: The protective effects of estrogen on AAAs can be
divided into central and peripheral estrogen effects depending on the site
of estrogen synthesis. Central estrogen synthesis from the ovaries accounted
for the majority of the protective effects of estrogen, while peripheral
estrogen conversion accounted for only one-third of the effect. These ﬁnd-
ings may explain the increased incidence of AAAs in postmenopausal
women lacking central estrogen synthesis.
National Trends in Endovascular and Open Renal Artery Interventions
for Renal Artery Stenosis and the Impact of Recent Randomized
Controlled Trials
Saqib Zia, Muhammad Asad Khan, Kuldeep Singh, Jonathan Schor,
Jonathan Deitch. Staten Island University Hospital, Staten Island, NY
Objectives: Recent randomized controlled trials (RCTs) like ASTRAL
and STAR show no clear beneﬁt of endovascular renal artery intervention
(ERAI) on renovascular disease progression or blood pressure control
compared with medical treatment. We wanted to analyze their impact on
the national trends in ERAI and open renal artery interventions (ORAI).
Methods: Nationwide Inpatient Sample was analyzed from 2007 to
2010 to identify patients undergoing ERAI or ORAI on yearly basis around
the publications of RCTs. Patient demographics, comorbidities, length of
stay, in hospital complications, and mortality were compared among
ERAI and ORAI patients using c2 and independent t-test.
Results: 71,396 patients underwent renal artery interventions from
2007 to 2010. Sixty-nine thousand eight-hundred and four (97.7%)
ERAI and 1421 (2%) ORAI. One-hundred seventy-one (0.3%) had both
and were excluded. ERAI patients were older (71.5 6 10.8 vs 64.6 6
12.3 years; P < .001) and had higher incidence of comorbidities including
diabetes mellitus (32.2% vs 13.9%; P < .001), hypertension (45.5% vs
39.1%; P < .001), coronary artery disease (57.4% vs 28.1%; P <.001),
and obesity (5.5% vs 0.1%; P < .001). ORAI patients had higher incidence
of smoking (26.2% vs 15.6%; P < .001) and chronic obstructive pulmonary
disease (24.1% vs 19.2%; P < .001). The number of ERAI decreased by
53.5% (22,824 vs 10,593) from 2007 to 2010. This decline was progressive
with 10.3% (22824 vs 20482) decrease from 2007 to 2008, 22.3% (20482
vs 15905) from 2008 to 2009 and the most signiﬁcant decrease of 33.4%
(15905 vs 10593) from 2009 to 2010 corresponded with the publication
of ASTRAL and STAR. In contrast to the sharp decline in ERAI, only
15.7% (343 vs 289) decline was seen in ORAI from 2007 to 2010.
ORAI patients had longer hospital stay and higher in hospital complications
and mortality (Table).
Conclusions: There is a progressive decline in ERAI nationally corre-
sponding with publication of recent RCTs. The trend is signiﬁcant even
with all limitations including selection bias in these trials. There is a great
need and anticipation of a better designed RCT to look at the efﬁcacy of
ERAI for renal artery stenosis before abandoning it.
Table. Yearly national trends and comparison of endovascular and open
renal artery interventions
ERAI ORAI P valueIndex year
2007 22824 (32.7%) 343 (24.1%)
2008 20482 (29.3%) 421 (29.6%)
2009 15905 (22.8%) 368 (25.9%)
2010 10593 (15.2%) 289 (20.3%)Mean age, years 71.5 6 10.8 64.6 6 12.3 <.001
Mean hospital stay, days 4.1 6 5.4 9.9 6 7.6 <.001
In-hospital mortality 596 (0.9%) 109 (7.7%) <.001
Hemorrhage 785 (1.1%) 46 (3.2%) <.001
Pneumonia 45 (0.1%) 35 (2.3%) <.001
Cardiac complication 543 (0.8%) 94 (6.6%) <.001
Renal failure 253 (0.4%) 70 (4.9%) <.001
Infection 143 (0.2%) 25 (1.8%) <.001Scientiﬁc Session II: Dialysis
Elderly Patients Started on Hemodialysis with a Tunneled Dialysis
Catheter Have Similar Long-Term Survival after Arteriovenous
Fistula or Arteriovenous Graft Placement
Theodore H. Yuo, Rabih A. Chaer, Ellen D. Dillavou, Luke K. Marone,
Michel S. Makaroun. University of Pittsburgh, Pittsburgh, PaObjectives: SVS guidelines suggest dialysis through arteriovenous
ﬁstula (AVF) is associated with a survival advantage over arteriovenous graft
(AVG). However, AVF often require months to become functional,
increasing tunneled dialysis catheter (TDC) use in patients starting hemodi-
alysis (HD) with TDC. We sought to compare survival in patients with end-
stage renal disease (ESRD) based on HD access type.
Methods: Using US Renal Data System databases, we identiﬁed inci-
dent HD patients in 2005 and followed them through 2008. Initial access
type was assessed using USRDS data collection forms. Attempts at AVF and
AVG creation were identiﬁed by current procedural terminology codes.
Patients were divided into groups based on whether an attempt at AVF
or AVG was undertaken within 3 months after initiation of HD. Log-
rank tests were used for pairwise survival comparisons, stratiﬁed by age.
The primary outcome was vital status.
Results: We analyzed 46,672 patients who started HD in 2005 and
survived at least 3 months. TDC was the initial access for 80% of patients;
52% were 65 years or older. At 1 year, patients starting HD with AVF
had improved survival compared with patients who initiated HD through
TDC (88% vs 76%; P < .001) or through AVG (88% vs 83%; P < .001).
In patients over 65 who initiate HD with TDC, creation of AVF and
AVG are associated with identical survival (P ¼ NS), with both signiﬁcantly
better than continued HD through TDC (P < .001) (Fig).
Conclusions: Initiation of HD through AVF is associated with
improved survival compared with AVG and TDC, but is a small fraction
of ESRD patients. In patients over 65 that initiate HD through TDC, crea-
tion of AVF is not superior to AVG in terms of survival.
Fig.Creation of an Artiﬁcial Artery Using Adipose-Derived Stem Cells
(ASCs) and Small Intestine Submucosa (SIS)
Kathleen M. Lamba, Aleksandra Polichaa, Lily Changa, Masaya Jimboa, Ping
Zhanga, Babak Abaia, Dawn Salvatorea, Thomas Tulenkob, Paul DiMuzioa.
aThomas Jefferson University Hospital, Philadelphia, Pa; bCooper
University Hospital, Camden, NJ
Objectives: We have previously investigated the use of ASCs differen-
tiated toward an endothelial cell lineage in the creation of a tissue-engi-
neered vascular graft. In this study, we report progress toward adding
a medial layer to the artiﬁcial artery, composed of the same autologous
ASCs, but differentiated toward a smooth muscle cell (SMC) lineage.
Such a layer may improve the strength, endothelial function, and anti-
inﬂammatory properties of the conduit.
Methods: ASC isolated from vascular patients via peri-umbilical lipo-
suction were differentiated toward SMC lineage using transforming growth
factor-b1. Phenotypic evaluation included polymerase chain reaction and
immunoblot for SMC-speciﬁc markers (a-actin, calponin, myosin heavy
chain). Contractile function was evaluated using a collagen lattice gel. SIS
vascular scaffolds (Cook Biotech, Inc, West Lafayette, Ind) seeded with
ASC-SMC (outside surface) and ASC- endothelial cell (luminal surface)
were ﬂow conditioned over 5 days within a bioreactor (up to 9 dynes,
120% stretch). Cell morphology and retention was evaluated using confocal
microscopy.
Results: ASC newly acquired SMC message and protein markers
following in vitro culture in TGF-b1 medium, although myosin heavy chain
expression was only variably expressed after 2 weeks of differentiation,
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ASC-SMC demonstrated a 12% increase in contraction when plated onto
a collagen gel (P ¼ .04). Cells seeded onto the SIS scaffold and ﬂow condi-
tioned for 5 days exhibited extensive cellular retention and orientation in the
direction of ﬂow on both the abluminal and luminal surfaces (Fig).
Conclusions: These data demonstrate (1) the potential of autologous
ASC to acquire SMC characteristics (molecular markers, contraction) in
response to growth factor stimulation; and (2) the creation of a multilayered,
tissue-engineered vascular graft from a single, autologous adult stem cell
source. In vivo investigation of the graft within a canine model to evaluate
the addition of the medial layer is underway.
Fig.Efﬁcacy of Axillary to Femoral Vein Bypass in Relieving Venous
Hypertension in Dialysis Patients with Symptomatic Central Vein
Occlusion
Joshua C. Grimm, Robert J. Beaulieu, Ibrahim S. Sultan, Mahmoud B.
Malas, Thomas Reifsnyder. The Johns Hopkins Hospital, Baltimore, Md
Objectives: Central vein stenosis or occlusion remains an unfortunate
complication associated with the use of dialysis catheters. The risk is not trivial
as nearly 80% of patients commence therapy via a central venous catheter. In
patients with a functioning arteriovenous ﬁstula, central vein stenosis can lead
to debilitating arm, and breast and/or neck swelling. Treatment typically
involves central vein angioplasty and/or stenting, but restenosis and reocclu-
sion rates remain high. Presented here are the initial results of a unique series
of patients with a mature arteriovenous access and symptomatic upper
extremity venous hypertension who, after having failed endovascular therapy,
were treated with axillary vein to femoral vein bypass.
Methods: This is a retrospective analysis of seven hemodialysis patients
with functioning right upper extremity access who underwent axillary vein to
femoral vein bypass between December 2011 and January 2013. Indications
for venous bypass included upper extremity swelling in ﬁve of the patients and
a combination of breast and upper extremity swelling in two of the patients.
Results: The median age was 60 years (range, 42-82) and ﬁve of seven
patients were male. The etiology of end-stage renal disease (ESRD) included
hypertension (2), diabetes (2), lupus nephritis (2), and focal segmental glo-
merulosclerosis (1). At least ﬁve of the patients had documentation of prior
central venous catheter placement and all seven underwent a previous endo-
vascular procedure, which was either unsuccessful or technically unfeasible.
Ringed polytetraﬂuoroethylene was used in all seven cases and the average
hospital stay was 1.8 days (range, 1-3). All seven patients experienced resolu-
tion of their swelling, and there have been no major graft complications.
Conclusions: Axillofemoral venous bypass is a safe and effective treat-
ment option for the dialysis patient with symptomatic venous hypertension
due to central vein occlusion.
Early Surgical Thrombectomy Improves Hemodialysis Vascular Access
Salvage
Nirvana Sadaghianlooa, Elixène Jean-Baptistea, Hacène Gaïdb, Mohammed
S. Islama, Christophe Robinob, Serge Declemya, Alan Dardikc, Réda
Hassen-Khodjaa. aUniversity of Nice Sophia Antipolis, Nice, France;
bPrincesse Grace Hospital Center, Monte Carlo, Monaco; cYale School of
Medicine, New Haven, Conn
Objectives: Hemodialysis vascular access (HVA) salvage after acute
thrombosis raises a debate between nephrologists and vascular surgeons
regarding the urgency of treatment. To assess the impact of early surgical
thrombectomy on the rate of HVA salvage, we offered an early surgical
protocol to eligible patients with acute HVA thrombosis.
Methods: Between January 2007 and October 2012, a total of 114
surgical thrombectomy attempts were performed on 82 patients to salvage
89 HVA. Time between the diagnosis of thrombosis and the admission inthe operation suite (T1), time between the diagnosis and the following dialysis
session (T2), and clinical and biological parameters were collected prospec-
tively for retrospective analysis. The main outcome measure was technical
success. Kaplan-Meier survival analysis estimated functional patency rates.
Results: Mean duration T1 was 5 hours 42 minutes (64 hours 24
minutes).Overall technical success ratewas 81% (92/114). A short-term cath-
eterwas placed following20 technical failures (18%).MeandurationT2was17
hours 18minutes (68 hours 48minutes). Early thrombectomywithin 6 hours
after diagnosis had a signiﬁcantly higher technical success rate (86%) compared
with thrombectomyperformed$6hours (69%;OR, 2.96; 95%CI, 1.10-7.97;
P¼ .03, logistic regression). Previous thrombosiswas also associatedwith tech-
nical failure (OR, 0.32; 95% CI, 0.12-0.86; P ¼ .02), whereas type of graft
(autologous/prosthetic) was not (P ¼ .89). The 30-day mortality rate was
2% (2/114). Mean patient follow-up was 22 6 18 months. Primary patency
rates were 56%6 7% and 41%6 7% at 1 and 2 years, respectively. Secondary
patency rates were 74% 6 7% and 56% 6 7% at 1 and 2 years, respectively.
Autologous ﬁstulae had higher secondary patency rates compared with pros-
thetic grafts (HR, 0.38; 95% CI, 0.18-0.82; P ¼ .01, Cox model).
Conclusions: With early surgical thrombectomy, there are increased
rates of HVA salvage that predict less reliance on catheter usage for
hemodialysis.
Fistula Maturation Algorithm Based upon Anatomic Fistula Location
Elizabeth Pensler, Yevgeniy Rits, Jeffrey Rubin. DMC/Wayne State
University School of Medicine, Detroit, Mich
Objectives: Initiation of dialysis therapy using autologous access is
crucial for establishing successful long-term dialysis therapy. The lead time
that is required for construction of the fully functional dialysis access prior
to dialysis is currently unknown. We have proposed to establish a lead
time algorithm for ﬁstula creation to be used based upon the anatomic loca-
tion of the ﬁstula as well as the type of conduit.
Methods: We reviewed the data for dialysis access creation over a 1-
year period in an inner city hospital. All patients prior to access placement
underwent arterial physiologic testing, arterial measurement, and venous
mapping. Criteria for use of venous conduits required vein diameters greater
than 2.5 mm. Arterial use was based upon a greater than 2-mm diameter as
well as appropriate physiologic parameters include extremity, hand, and
digital pressure measurements with and without radial and ulnar compres-
sion testing. A maturation algorithm was created, which was based upon
anatomic locations and essential preoperative factors.
Results: Over a 1-year period, 103 access procedures were performed.
There was a 60% rate for primary ﬁstula creation. Fifteen radiocephalic, 26
basilic vein transpositions, and 20 brachiocephalic primary access procedures
were performed, the rest were brachio-axillary grafts. Over this period, seven
accesses failed, three were lost to follow-up, and one patient died. The
average maturation time for all access procedures was 5.3 weeks. The
longest time to maturation involved the radiocephalic ﬁstula group, and
this required 10.3 weeks. Brachiocephalic ﬁstula maturation occurred an
8.6 weeks, and basilic vein transposition in 6.7 weeks. Prosthetic grafts
required 2.9 weeks until they were usable.
Conclusions: Based upon these results, we established the following
algorithm. All patients that reached chronic kidney disease stage IV that
were referred for access creation immediately underwent arterial and venous
ultrasound. Based upon vein suitability, patients were stratiﬁed into four
groups. Primary radiocephalic ﬁstula requires the longest time for full matu-
ration and suitability for use, followed by brachiocephalic and basilic vein
transposition. We, therefore, recommend patient referral to access centers
at least 6 months prior to anticipated dialysis requirement if we are to main-
tain the highest standards that have been established for the creation of
primary/autogenous arteriovenous ﬁstulas in this patient population.
Cost Discrepancies in the Creation and Maintenance of Functional
Arteriovenous Fistulas
Steven D. Abramowitz, Angela A. Kokkosis, Harry Schanzer, Peter L.
Faries, Michael M. Marin, Victoria J. Teodorescu. Mount Sinai Hospital,
New York, NY
Objectives: The National Kidney Foundation-Dialysis Outcomes
Quality Initiative recommends the preferential creation of arteriovenous
ﬁstulas (AVF) for hemodialysis access. Achieving and maintaining functional
patency of preferred hemodialysis access is a challenge for vascular surgeons
and a large healthcare expense. We sought to explore age-related and
gender-related differences in the costs of creating and of maintaining radio-
cephalic (RCF), brachiocephalic (BCF), and brachiobasilic (BBF) AVFs.
Methods: A prospectively maintained institutional database identiﬁed
348 patients undergoing access creation between 2004 and 2011 with 2
years of documented functional patency from the date of creation. Medical
records were analyzed for central venous catheter events, access-related
